Logotipo do repositório
 

Publicação:
Involvement of central alpha(1)-adrenoceptors on renal responses to central moxonidine and alpha-methylnoradrenaline

dc.contributor.authorAndrade, Carina A. F. de [UNESP]
dc.contributor.authorAndrade, Glaucia M. F. de [UNESP]
dc.contributor.authorDe Paula, Patricia M. [UNESP]
dc.contributor.authorDe Luca, Laurival A. [UNESP]
dc.contributor.authorMenani, José Vanderlei [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-20T13:46:06Z
dc.date.available2014-05-20T13:46:06Z
dc.date.issued2009-04-01
dc.description.abstractMoxonidine (alpha(2)-adrenoceptor/imidazoline receptor agonist) injected into the lateral ventricle induces diuresis, natriuresis and renal vasodilation. Moxonidine-induced diuresis and natriuresis depend on central imidazoline receptors, while central alpha(1)-adrenoceptors are involved in renal vasodilation. However, the involvement of central alpha(1)-adrenoceptors on diuresis and natriuresis to central moxonidine was not investigated yet. In the present study, the effects of moxonidine, alpha-methylnoradrenaline (alpha(2)-adrenoceptor agonist) or phenylephrine (alpha(1)-adrenoceptor agonist) alone or combined with previous injections of prazosin (alpha(1)-adrenoceptor antagonist), yohimbine or RX 821002 (alpha(2)-adrenoceptor antagonists) intracerebroventricularly (i.c.v.) on urinary sodium, potassium and volume were investigated. Male Holtzman rats (n = 5-18/group) with stainless steel cannula implanted into the lateral ventricle and submitted to gastric water load (10% of body weight) were used. Injections of moxonidine (20 nmol) or alpha-methylnoradrenaline (80 nmol) i.c.v. induced natriuresis (196 +/- 25 and 171 +/- 30, respectively, vs. vehicle: 101 +/- 9 mu Eq/2 h) and diuresis (9.0 +/- 0.4 and 12.3 +/- 1.6, respectively, vs. vehicle: 5.2 +/- 0.5 ml/2 h). Pre-treatment with prazosin (320 nmol) i.c.v. abolished the natriuresis (23 +/- 4 and 76 +/- 11 mu Eq/2 h, respectively) and diuresis (5 +/- 1 and 7.6 +/- 0.8 ml/2 h, respectively) produced by i.c.v. moxonidine or alpha-methylnoradrenaline. RX 821002 (320 nmol) i.c.v. abolished the natriuretic effect of alpha-methylnoradrenaline, however, yohimbine (320 nmol) did not change renal responses to moxonidine. Phenylephrine (80 nmol) i.c.v. induced natriuresis and kaliuresis that were blocked by prazosin. Therefore, the present data suggest that moxonidine and alpha-methylnoradrenaline acting on central imidazoline receptors and alpha(2)-adrenoceptors, respectively, activate central alpha(1)-adrenergic mechanisms to increase renal excretion. (C) 2009 Elsevier B.V. All rights reserved.en
dc.description.affiliationSão Paulo State Univ, UNESP, Sch Dent, Dept Physiol & Pathol, BR-14801903 Araraquara, SP, Brazil
dc.description.affiliationUnespSão Paulo State Univ, UNESP, Sch Dent, Dept Physiol & Pathol, BR-14801903 Araraquara, SP, Brazil
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipIdFAPESP: 99/01272-5
dc.description.sponsorshipIdFAPESP: 06/50803-9
dc.format.extent60-67
dc.identifierhttp://dx.doi.org/10.1016/j.ejphar.2009.01.039
dc.identifier.citationEuropean Journal of Pharmacology. Amsterdam: Elsevier B.V., v. 607, n. 1-3, p. 60-67, 2009.
dc.identifier.doi10.1016/j.ejphar.2009.01.039
dc.identifier.issn0014-2999
dc.identifier.lattes1023597870118105
dc.identifier.urihttp://hdl.handle.net/11449/16282
dc.identifier.wosWOS:000265123500010
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofEuropean Journal of Pharmacology
dc.relation.ispartofjcr3.040
dc.relation.ispartofsjr1,057
dc.rights.accessRightsAcesso restrito
dc.sourceWeb of Science
dc.subjectSodium excretionen
dc.subjectUrinary excretionen
dc.subjectAdrenoceptoren
dc.subjectRenal excretionen
dc.subjectPrazosinen
dc.titleInvolvement of central alpha(1)-adrenoceptors on renal responses to central moxonidine and alpha-methylnoradrenalineen
dc.typeArtigo
dcterms.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dcterms.rightsHolderElsevier B.V.
dspace.entity.typePublication
unesp.author.lattes1023597870118105
unesp.author.lattes9055280555067656[1]
unesp.author.orcid0000-0001-5433-4493[3]
unesp.author.orcid0000-0003-1167-4441[5]
unesp.author.orcid0000-0003-3393-2202[1]
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Odontologia, Araraquarapt
unesp.departmentFisiologia e Patologia - FOARpt

Arquivos

Licença do Pacote

Agora exibindo 1 - 2 de 2
Carregando...
Imagem de Miniatura
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Carregando...
Imagem de Miniatura
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição: